In the Claims

1. (Previously presented): A compound having the structure:



wherein:

A^1 is independently selected from $C(R^2)_2$, CR^2OR, $CR^2OC(=O)R$, $C(=O)$, $C(=S)$, CR^2SR, and $C(=NR)$,

A^2 is independently selected from $C(R^2)_2$–$C(R^3)_2$, $C(R^2)$=$C(R^3)$ and $C(=O)C(R^3)_2$;

Q is CR^4;



;

L is selected from a bond, O, S, S–S, S(=O), $S(=O)_2$, $S(=O)_2NR$, NR, N–OR, C_1–C_{12} alkylene, C_1–C_{12} substituted alkylene, C_2–C_{12} alkenylene, C_2–C_{12} substituted alkenylene, C_2–C_{12} alkynylene, C_2–C_{12} substituted alkynylene, C(=O)NH, OC(=O)NH, NHC(=O)NH, C(=O), $C(=O)NH(CH_2)_n$, or $(CH_2CH_2O)_n$, where n is optionally 1, 2, 3, 4, 5, or 6;

X is selected from O, S, NH, NR, N–OR, $N–NR_2$, $N–CR_2OR$ and $N–CR_2NR_2$;

Ar is selected from (a) a C_3–C_{12} carbocycle, C_3–C_{12} substituted carbocycle, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl;

or (b) a saturated, unsaturated or aromatic ring or ring system having a mono- or bicyclic carbocycle or heterocycle containing 3 to 12 ring atoms;

R^2, R^3 and R^4 are each independently selected from H, F, Cl, Br, I, OH, $–NH_2$, $–NH_3^+$, –NHR, $–NR_2$, $–NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $–SO_2R$, $–SO_2Ar$, –SOAr, –SAr, $–SO_2NR_2$, –SOR, $–CO_2R$, $–C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, –CN, $–N_3$, $–NO_2$, C_1–C_8

alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_3–C_{12} carbocycle, C_3–C_{12} substituted carbocycle, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety;

when taken together on a single carbon, two R^2 or two R^3 may form a spiro ring;

R^1 is independently selected from CR_3, $NRSO_2R$, $OC(=O)NR_2$ $OC(=O)R$, SR, H, F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, $-NHR$, $-NR_2$, $-NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, $-SOAr$, $-SAr$, $-SO_2NR_2$, $-SOR$, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, $-CN$, $-N_3$, $-NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_3–C_{12} carbocycle, C_3–C_{12} substituted carbocycle, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety;

R is independently selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety;

R^{X2} is independently selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, a prodrug moiety, and a protecting group;

and the tautomers, salts, solvates, resolved enantiomers and purified diastereomers thereof;

with the proviso that when Y=Z is C=C(OH), X is O, A^1 is C(=O), A^2 is $C(R^2)=C(R^3)$, and Q is CH, then L is not a bond.

2. (Previously presented): A compound of claim 1 selected from the structures:













and



3. (Previously presented): A compound of claim 1 wherein A^1 is CH_2.

4. (Previously presented): A compound of claim 1 wherein Ar is a saturated, unsaturated or aromatic ring or ring system having a mono- or bicyclic carbocycle or heterocycle containing 3 to 12 ring atoms.

5. (Previously presented): A compound of claim 1 wherein R^1 is selected from R, OR, NR_2, NHR, $NHSO_2R$ and $NRSO_2R$.

6. (Previously presented): A compound of claim 1 selected from the structures:





and



7. (Previously presented): A compound of claim 1 wherein R^{x2} is a protecting group selected from the group consisting of benzyhydryl ($CHPh_2$), trialkylsilyl (R_3Si), 2-trimethylsiloxyethyl, alkoxymethyl (CH_2OR), and ester (C(=O)R).

8. (Previously presented): A compound of claim 1 having the structure:



9. (Previously presented): A compound of claim 1 having Formula I:



I.

wherein R^{x2} is H and X is O.

10. (Previously presented): A compound of claim 1 wherein L is not a bond.

11. (Previously presented): A compound of claim 1 wherein R^4 is H.

12. (Previously presented): A compound of claim 1 wherein Ar is $C_6 - C_{20}$ substituted aryl.

13. (Previously presented): A compound of claim 1 having at least one phosphonate group.

14. (Previously presented): A compound of claim 1 wherein substituted alkyl, substituted alkylene, substituted alkyenylene, substituted alkynylene, substituted carbocycle, substituted aryl, and substituted heteroaryl are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, $-NHR$, $-NR_2$, $-NR_3^+$, C_1-C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1-C_8 alkylsulfonate, C_1-C_8 alkylamino, 4-dialkylaminopyridinium, C_1-C_8 alkylhydroxyl, C_1-C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, $-SOAr$, $-SAr$, $-SO_2NR_2$, $-SOR$, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, $-CN$, $-N_3$, $-NO_2$, C_1-C_8 alkoxy, C_1-C_8 trifluoroalkyl, C_1-C_8 alkyl, C_3-C_{12} carbocycle, C_6-C_{20} aryl, C_2-C_{20} heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.

15. (Previously presented): The compound of claim 1 wherein A^1 is CH_2, $C(CH_3)_2$,



, CH_2–CH_2, $C(CH_3)_2$–CH_2, or CH_2–CH_2–CH_2 .

16. (Previously presented): The compound of claim 9 wherein X is O; L is CH_2; and Ar is substituted phenyl.

17. (Previously presented): The compound of claim 16 wherein Ar is 4-fluorophenyl.

18. (Previously presented): The compound of claim 9 wherein X is O; and R^2, R^3 and R^4 are each H.

19. (Previously presented): The compound of claim 9 wherein X is O; A^1 is CH_2; and R^2, R^3 and R^4 are each H.

20. (Previously presented): The compound of claim 1 wherein Ar-L is selected from the structures:



and



21. (Previously presented): A compound of claim 9 having Formula Ia:



Ia

22. (Previously presented): A compound of claim 9 having the structure:



23. (Previously presented): A compound of claim 22 selected from the structures:



and



24. (Previously presented): A compound of claim 9 wherein AR-L is para-fluorobenzyl.

25. (Previously presented): A compound of claim 9 having the structure:



with the proviso that when R^1 is OH, and R^2, R^3, and R^4 are H, then L is not a bond.

26. (Previously presented): A compound of claim 1 wherein

R^1 is selected from CR_3, $C(=O)NR_2$, $OC(=O)OR$, $OC(=O)NR_2$, $OC(=O)R$, OSO_2NR_2 (sulfamate), NR_2, $NRSO_2R$, SR, S(O)R, SO_2R and SO_2NR_2 (sulfonamide).

27. (Previously presented): The compound of claim 26 wherein at least one R is a prodrug moiety.

28. (Previously presented): A compound of claim 1 wherein at least one of R^1, R^2, R^3, and R^4 is selected from the structures:



29. (Previously presented): A compound of claim 1 wherein at least one of R^1, R^2, R^3, and R^4 is selected from the structures:



30. (Previously presented): A compound of claim 1 wherein at least one of R^1, R^2, R^3, and R^4 is selected from the structures:



31. (Previously presented): A compound of claim 1 wherein at least one of R^1, R^2, R^3, and R^4 is a lactam having the structures:



and



, or

a sultam having the structures:



and



.

32. (Previously presented): A compound of claim 1 wherein Ar is selected from the structures:





and

where the wavy line ~ indicates the covalent attachment site to L.

33. (Previously presented): A compound of claim 1 wherein Ar is selected from the structures:



and

where n is 1 to 6.

34. (Previously presented): A compound of claim 1 wherein Ar is selected from the structures:



35. (Previously presented): A compound of claim 1 comprising a prodrug moiety selected from the structures:



wherein R^5 is $-CR_2CO_2R^7$ where R^6 and R^7 are independently H or C_1–C_8 alkyl.

36. (Previously presented): The compound of claim 1 comprising a phosphonate or prodrug moiety having the structure:



wherein:

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)_2$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)_2)$, -S(O)- (sulfoxide), $-S(O)_2-$ (sulfone), -S- (sulfide), or -S-S- (disulfide);

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;

R^y is independently H, C_1–C_6 alkyl, C_1–C_6 substituted alkyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, or a protecting group, or where taken together at a carbon atom, two vicinal R^y groups form a carbocycle or a heterocycle; and

R^x is independently H, C_1–C_6 alkyl, C_1–C_6 substituted alkyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, or a protecting group, or the formula:



;

where M1a, M1c, and M1d are independently 0 or 1, and M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

37. (Previously presented): The compound of claim 36 wherein the phosphonate or prodrug moiety has the structure:



38. (Previously presented): The compound of claim 37 wherein the phosphonate or prodrug moiety has the structure:



where Y^{2b} is O or $N(R^x)$.

39. (Previously presented): The compound of claim 37 wherein the phosphonate or prodrug moiety has the structure:



;

where W^5 is a carbocycle, and Y^{2c} is O, $N(R^y)$ or S.

40. (Previously presented): The compound of claim 39 wherein W^5 is selected from the structures:



41. (Previously presented): The compound of claim 37 wherein the phosphonate or prodrug moiety has the structure:



42. (Previously presented): The compound of claim 1 wherein the phosphonate or prodrug moiety has the structure:



wherein Y^{2b} is O or N(R^x); M12d is 1, 2, 3, 4, 5, 6, 7 or 8; R^1 is H or C_1–C_6 alkyl; and the phenyl carbocycle is substituted with 0 to 3 R^2 groups where R^2 is C_1–C_6 alkyl or substituted

alkyl.

43. (Previously presented): The compound of claim 1 wherein the phosphonate or prodrug moiety has the structure:



or


44. (Previously presented): The compound of claim 36 wherein R^x is selected from the structures:



and


45. (Currently amended): A compound ~~of~~ selected from the structures:



2



3



4



9



11



15



17



18



19



21



22



23



24

and



25

46. (Previously presented): A compound of claim 1 wherein none of R^2, R^3, R^4, R, or R^{x2} is a prodrug moiety.

47. (Currently amended): A compound ~~of~~ selected from the structures:



48



51



52



53



55



58



60



62



64



66



68



70



72



74



76



79



81



83



85



87



89



91



93



95



97



99



101



103



105



108



110



112



114



116



118



120



122



125



128



130



132



135



137



139



141



143



145



147



203



204



206



209



210



211



226



228



230



232



234



236



238



240



263



265



267



269



271



273



274



276



278



280



282



284



285



287



289



290



296



298



300



306



308



310



313



316



317



318



319



320



321

and



322

48. (Previously presented): A compound selected from the structures:



26



149



151



153



155



157



158



160



165



169



170



177



180



184



189



190



194



215



217



221



222



224



292



293



294



314

and



315

49. (Currently amended): A compound having the structure:



wherein:

A^1 is independently selected from $C(R^2)_2$, CR^2OR, $CR^2OC(=O)R$, $C(=O)$, $C(=S)$, CR^2SR, and $C(=NR)$,

A^2 is independently selected from $C(R^2)_2$–$C(R^3)_2$, $C(R^2)=C(R^3)$, and $C(=O)C(R^3)_2$;

Q is CR^4;



;

L is selected from a bond, O, S, S–S, S(=O), $S(=O)_2$, $S(=O)_2NR$, NR, N–OR, C_1–C_{12} alkylene, C_1–C_{12} substituted alkylene, C_2–C_{12} alkenylene, C_2–C_{12} substituted alkenylene, C_2–C_{12} alkynylene, C_2–C_{12} substituted alkynylene, C(=O)NH, OC(=O)NH, NHC(=O)NH, C(=O), $C(=O)NH(CH_2)_n$, or $(CH_2CH_2O)_n$, where n is optionally 1, 2, 3, 4, 5, or 6;

X is selected from O, S, NH, NR, N–OR, $N–NR_2$, $N–CR_2OR$ and $N–CR_2NR_2$;

Ar is selected from (a) a C_3–C_{12} carbocycle, C_3–C_{12} substituted carbocycle, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl;

or (b) a saturated, unsaturated or aromatic ring or ring system having a mono- or bicyclic carbocycle or heterocycle containing 3 to 12 ring atoms;

R^2, R^3 and R^4 are each independently selected from H, F, Cl, Br, I, OH, $–NH_2$, $–NH_3^+$, –NHR, $–NR_2$, $–NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $–SO_2R$, $–SO_2Ar$, –SOAr, –SAr, $–SO_2NR_2$, –SOR, $–CO_2R$, $–C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, –CN, $–N_3$, $–NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_3–C_{12} carbocycle, C_3–C_{12} substituted carbocycle, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, and phosphate;

when taken together on a single carbon, two R^2 or two R^3 may form a spiro ring;

R^1 is independently selected from CR_3, $NRSO_2R$, $OC(=O)NR_2$ $OC(=O)R$, SR, H, F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, -NHR, $-NR_2$, $-NR_3^+$, C_1-C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1-C_8 alkylsulfonate, C_1-C_8 alkylamino, 4-dialkylaminopyridinium, C_1-C_8 alkylhydroxyl, C_1-C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, -SOAr, -SAr, $-SO_2NR_2$, -SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, -CN, $-N_3$, $-NO_2$, C_1-C_8 alkoxy, C_1-C_8 trifluoroalkyl, C_1-C_8 alkyl, C_1-C_8 substituted alkyl, C_3-C_{12} carbocycle, C_3-C_{12} substituted carbocycle, C_6-C_{20} aryl, C_6-C_{20} substituted aryl, C_2-C_{20} heteroaryl, and C_2-C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, and phosphate;

R^1 is independently selected from CR_3, $NRSO_2R$, $OC(=O)OR$, $OC(=O)NR_2$ $OC(+O)R$, SR, H, F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, -NHR, $-NR_2$, $-NR_3^+$, C_1-C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1-C_8 alkylsulfonate, C_1-C_8 alkylamino, 4-dialkylaminopyridinium, C_1-C_8 alkylhydroxyl, C_1-C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, -SOAr, -SAr, $-SO_2NR_2$, -SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, -CN, $-N_3$, $-NO_2$, C_1-C_8 alkoxy, C_1-C_8 trifluoroalkyl, C_1-C_8 alkyl, C_1-C_8 substituted alkyl, C_3-C_{12} carbocycle, C_3-C_{12} substituted carbocycle, C_6-C_{20} aryl, C_6-C_{20} substituted aryl, C_2-C_{20} heteroaryl, and C_2-C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, and phosphate;

R is independently selected from H, C_1-C_8 alkyl, C_1-C_8 substituted alkyl, C_6-C_{20} aryl, C_6-C_{20} substituted aryl, C_2-C_{20} heteroaryl, and C_2-C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, and phosphate;

R^{X2} is independently selected from H, C_1-C_8 alkyl, C_1-C_8 substituted alkyl, C_6-C_{20} aryl, C_6-C_{20} substituted aryl, C_2-C_{20} heteroaryl, and C_2-C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, and phosphate;

and the tautomers, salts, solvates, resolved enantiomers and purified diastereomers thereof;

with the proviso that when Y=Z is C=C(OH), X is O, A^1 is C(=O), A^2 is $C(R^2)=C(R^3)$, and Q is CH, then L is not a bond[[.]]; and

P is a protecting group selected from benzyhydryl ($CHPh_2$), trialkylsilyl (R_3Si), 2-trimethylsiloxyethyl, alkoxymethyl (CH_2OR), and ester (C(=O)R).

50. (Previously presented): A process for preparation of a compound having the structure:



comprising reacting a succinimide compound having the structure:



with a heterocyclic compound having the structure:



and reacting with an acylation reagent having a formula selected from:

 and 

wherein:

A^2 is selected from $C(R^2)_2$–$C(R^3)_2$, $C(R^2)$=$C(R^3)$, and $C(=O)C(R^3)_2$;

Q is CR^4;

L is selected from a bond, O, S, NR, N–OR, C_1–C_{12} alkyldiyl, C_1–C_{12} substituted alkyldiyl, C(=O)NH, C(=O), S(=O), $S(=O)_2$, $C(=O)NH(CH_2)_n$, and $(CH_2CH_2O)_n$, where n ranges from 1 to 6;

Ar is selected from (a) a C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl or (b) a saturated, unsaturated or aromatic ring or ring system having a mono- or bicyclic carbocycle or heterocycle containing 3 to 12 ring atoms;

R^1 is selected from R, OR, NR_2, NHR, $NHSO_2R$, and $NRSO_2R$;

E is selected from Cl, imidazole, and hydroxybenzotriazole;

R^2, R^3 and R^4 are each independently selected from H, F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, $-NHR$, $-NR_2$, $-NR_3^+$, C_1-C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1-C_8 alkylsulfonate, C_1-C_8 alkylamino, 4-dialkylaminopyridinium, C_1-C_8 alkylhydroxyl, C_1-C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, $-SOAr$, $-SAr$, $-SO_2NR_2$, $-SOR$, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, $-CN$, $-N_3$, $-NO_2$, C_1-C_8 alkoxy, C_1-C_8 trifluoroalkyl, C_1-C_8 alkyl, C_1-C_8 substituted alkyl, C_3-C_{12} carbocycle, C_3-C_{12} substituted carbocycle, C_6-C_{20} aryl, C_6-C_{20} substituted aryl, C_2-C_{20} heteroaryl, and C_2-C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety; and

R is selected from C_1-C_6 alkyl, C_1-C_6 substituted alkyl, C_6-C_{20} aryl, C_6-C_{20} substituted aryl, C_2-C_{20} heteroaryl, C_2-C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.

51. (Previously presented): The process of claim 50 for preparation of a compound having the structure:



wherein the heterocyclic compound has the structure:



52. (Previously presented): A process for preparation of a compound having the structure:



comprising reacting a compound having the structure:



with a basic reagent comprising hydroxide, an alkoxide or an amine;

wherein:

A^1 is independently selected from $C(R^2)_2$, CR^2OR, $CR^2OC(=O)R$, $C(=O)$, $C(=S)$, CR^2SR, and $C(=NR)$,

A^2 is independently selected from $C(R^2)_2$–$C(R^3)_2$, $C(R^2)=C(R^3)$, and $C(=O)C(R^3)_2$;

Q is CR^4;

X is selected from O, S, NH, NR, N–OR, N–NR_2, N–CR_2OR and N–CR_2NR_2;

L is selected from a bond, O, S, NR, N–OR, C_1–C_{12} alkyldiyl, C_1–C_{12} substituted alkyldiyl, C(=O)NH, C(=O), S(=O), $S(=O)_2$, $C(=O)NH(CH_2)_n$, and $(CH_2CH_2O)_n$, where n ranges from 1 to 6;

Ar is selected from (a) a C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl;

or (b) a saturated, unsaturated or aromatic ring or ring system having a mono- or bicyclic carbocycle or heterocycle containing 3 to 12 ring atoms;

R^2, R^3 and R^4 are each independently selected from H, F, Cl, Br, I, OH, $–NH_2$, $–NH_3^+$, –NHR, $–NR_2$, $–NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $–SO_2R$, $–SO_2Ar$, –SOAr, –SAr, $–SO_2NR_2$, –SOR, $–CO_2R$, $–C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, –CN, $–N_3$, $–NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_3–C_{12} carbocycle, C_3–C_{12}

substituted carbocycle, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety; and

R is selected from C_1–C_6 alkyl, C_1–C_6 substituted alkyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.

53. (Previously presented): A process for preparation of a compound having structure 115:



115

comprising reacting a compound having the structure 44:



44

with tetrabutylammonium fluoride to form a desilylated intermediate; and

reacting the desilylated intermediate with triphosgene (bis(trichloromethyl) carbonate), followed by dimethylhydrazine to form structure 115.

54. (Previously presented): A compound of claim 1 substituted with phosphonate and capable of accumulating in human PBMC.

55. (Previously presented): The compound of claim 54 wherein the intracellular half-life of the compound or an intracellular metabolite of the compound in human PBMC is increased by at least about 50% when compared to the analog of the compound not having the phosphonate.

56. (canceled)

57. (canceled)

58. (Previously presented): The compound of claim 55 wherein the half-life is improved by at least about 100%.

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

63. (Previously presented): A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

64. (Previously presented): The pharmaceutical composition of claim 63 further comprising a therapeutically effective amount of an AIDS treatment agent selected from an HIV inhibitor agent, an anti-infective agent, and an immunomodulator.

65. (Previously presented): The pharmaceutical composition of claim 64 wherein the HIV inhibitor agent is an HIV-protease inhibitor.

66. (Previously presented): The composition of claim 64 wherein the HIV inhibitor agent is a nucleoside reverse transcriptase inhibitor.

67. (Previously presented): The composition of claim 64 wherein the HIV inhibitor agent is a non-nucleoside reverse transcriptase inhibitor.

68. (Previously presented): A process for making a pharmaceutical composition comprising combining a compound of claim 1 and a pharmaceutically acceptable carrier.

69. (Previously presented): A method of inhibiting HIV integrase, comprising the administration to a mammal in need of such treatment of a therapeutically effective amount of a compound of claim 1.

70. (Previously presented): A method of treating infection by HIV, or of treating AIDS or ARC, comprising administration to a mammal in need of such treatment of a therapeutically effective amount of a compound of claim 1.

71 – 79 (canceled)

80. (Previously presented): A compound having the structure:



wherein R^1 is selected from R, OR, NR_2, NHR, $NHSO_2R$ and $NRSO_2R$;

R^2, R^3 and R^4 are each independently selected from H, F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, –NHR, $-NR_2$, $-NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, –SOAr, –SAr, $-SO_2NR_2$, –SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, –CN, $-N_3$, $-NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_3–C_{12} carbocycle, C_3–C_{12} substituted carbocycle, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety; and

R is independently selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heteroaryl, and C_2–C_{20} substituted heteroaryl, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety;

and the tautomers, salts, solvates, resolved enantiomers and purified diastereomers thereof.

81. (new): Method of treating a disorder affecting white blood cells, comprising:

administering a compound of claim 1 comprising phosphonate prodrug to a patient in need of white-blood-cell targeting.

82. (new): Method of targeting a compound to white blood cells, comprising:

selecting a compound of claim 1 having a desired pharmaceutical activity and having a first structure;

modifying said first structure by replacing one or more atom of said first structure with an organic substituent comprising a phosphonate group or incipient phosphonate group to provide a compound having a second structure.

83. (new): A method of manufacturing an HIV inhibitor compound having both selectivity for white blood cells and a desired pharmaceutical activity, comprising:

chemically synthesizing a first molecule of claim 1 having a first structure containing a phosphonate or precursor phosphonate group, wherein said first structure differs from a second structure of a compound known to have said desired pharmaceutical activity by having at least one hydrogen atom of said second structure replaced by an organic substituent comprising a phosphonate group or incipient phosphonate group.

84. (new): The method of claim 83, wherein said first molecule is synthesized by a series of chemical reactions in which a hydrogen of said second structure is replaced by said organic substituent.

85. (new): The method of claim 83, wherein said first molecule is synthesized by a series of chemical reactions that never includes a molecule of said second structure.

86. (new): Method of accumulating an HIV integrase inhibitor compound inside a white blood cell, comprising:

administering to a sample a composition comprising a compound of claim 1.

87. (new): The method of claim 85 wherein said sample is a patient.

88. (new): The method of claim 83, wherein said compound has a chemical structure A-B, wherein (a) a compound having structure A-H has HIV integrase inhibitor activity and (b) substructure B comprises a phosphonate group or a precursor phosphonate group.

89. (new): Method of increasing half-life of an HIV integrase inhibitor compound, comprising:

replacing at least one hydrogen atom or organic radical of a compound of claim 1 by an organic substituent comprising a phosphonate group or incipient phosphonate.